Register
Community
Physicians
Editors
Experts
Code of conduct
Blog
Terms of Use
Privacy Policy
Sitemap
Company
About
Publications
Press
Careers
Programs
Journal Club
Targeted Topic
Clinical Trial
Tumor Board
Contact Us
Sign in
Pediatric Oncology
Pharmacology
Questions discussed in this category
When would you consider additional testing for NUDT15 and other polymorphisms related to 6-MP/6-TG metabolism, if not guided by a study protocol?
2 Answers available
12890
Papers discussed in this category
Pharmacogenomics,
Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
Pediatr Blood Cancer, 2011 Feb 22
A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.
Pediatr Blood Cancer, 2011 Jul 27
Pharmacogenetics, cost of genotyping, and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia.
Int J Hematol, 2021 Oct 28
NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China.
Pharmacogenet Genomics,
Cost-effectiveness analysis of pretreatment screening for NUDT15 defective alleles.
Related Topics in Pediatric Oncology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers